-       Report 
- October 2025
-  541 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- July 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  185 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
             -       Report 
- August 2025
-  193 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  192 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- December 2024
-  150 Pages 
- Global 
   From       €3444EUR$3,850USD£3,029GBP 
      €4338EUR$4,850USD£3,816GBP 
          -       Report 
- March 2025
-  371 Pages 
- Global 
   From       €3980EUR$4,450USD£3,501GBP 
          -       Report 
- January 2025
-  140 Pages 
- Global 
   From       €3533EUR$3,950USD£3,108GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- July 2025
-  257 Pages 
- Global 
   From       €4468EUR$4,995USD£3,930GBP 
            -       Report 
- February 2025
-  180 Pages 
- Global 
   From       €3687EUR$4,123USD£3,244GBP 
      €4338EUR$4,850USD£3,816GBP 
          -       Report 
- September 2025
-  120 Pages 
- United States 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- March 2025
-  131 Pages 
- Europe 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- March 2024
-  373 Pages 
- Global 
   From       €5118EUR$5,923USD£4,350GBP 
            -       Report 
- April 2024
-  84 Pages 
- Global 
   From       €1717EUR$1,920USD£1,511GBP 
      €2147EUR$2,400USD£1,888GBP 
            -       Report 
- October 2024
-  180 Pages 
- Global 
   From       €1717EUR$1,920USD£1,511GBP 
      €2147EUR$2,400USD£1,888GBP 
            -       Report 
- September 2024
-  210 Pages 
- Global 
   From       €1717EUR$1,920USD£1,511GBP 
      €2147EUR$2,400USD£1,888GBP 
            -       Report 
- November 2023
-  88 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
       
      Early Phase Studies are a critical part of the drug discovery process. They are the first step in the clinical development of a drug, and involve the testing of a drug's safety, efficacy, and pharmacokinetics in humans. Early Phase Studies are typically conducted in small groups of healthy volunteers or patients, and involve the administration of a single dose or multiple doses of the drug. The results of these studies are used to determine whether the drug is safe and effective for further clinical    development.
Early Phase Studies are conducted by a variety of companies, including contract research organizations (CROs), pharmaceutical companies, and biotechnology companies. These companies provide services such as clinical trial design, data management, and regulatory support. They also provide expertise in drug development, clinical trial management, and regulatory compliance.
Some of the companies in the Early Phase Study market include Parexel, Quintiles, Covance, PPD, ICON, and Syneos Health. Show Less   Read more